Participating centers have been announced, and are recruiting. The Dimebon trials will need 90 participants and will last three months.

The Announcement: DIMOND: A Multi-Center, Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects with Huntington's Disease

The Huntington Study Group (HSG) is conducting a study of the research medication Dimebon in persons 18 years of age or older who have mild to moderate Huntington's disease (HD). DIMOND is designed to determine safe and tolerable doses of Dimebon and also to determine the effect of Dimebon on cognitive (thinking) and motor (movement) signs and overall functioning of subjects with HD. Approximately 15 research centers in the United States and in the United Kingdom will enroll up to 90 research subjects and will last about 3 months. The study will enroll research subjects with early to moderate signs of HD who are independently ambulatory (walking) and self-sufficient in activities of daily living, such as eating, dressing, and bathing. Enrollment will begin in the Summer of 2007. The study is sponsored by Medivation, Inc.

If you are interested in learning more about this study, please contact the Huntington Study Group

1-800-487-7671, or see the July 2007 DIMOND press release.